Should We Use Prognostic Indices and/or Biomarkers to Guide Therapy in Follicular Lymphoma?

[11] Martínez-Laperche C, 2022, BMC CANCER, V22, DOI 10.1186/s12885-022-10070-z

[12] Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (30) : 3618 - +

[13] Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (12) : 1503 - 1510

[14] Lack of intrafollicular memory CD4+T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma [J]. BLOOD CANCER JOURNAL, 2021, 11 (07)

[15] Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial [J]. LANCET ONCOLOGY, 2020, 21 (11) : 1433 - 1442

[16] Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry [J]. LANCET ONCOLOGY, 2015, 16 (09) : 1111 - 1122

[17] Pettitt AR., 2019, HEMATOL ONCOL, V37, P67, DOI [DOI 10.1002/HON.35_2629, 10.1002/hon.35_2629]

[18] MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial [J]. LEUKEMIA, 2020, 34 (02) : 522 - 532

[19] Minimal Residual Disease Response at End of Induction and during Maintenance Correlates with Updated Outcome in the Phase III GALLIUM Study of Obinutuzumab- or Rituximab-Based Immunochemotherapy in Previously Untreated Follicular Lymphoma Patients [J]. BLOOD, 2018, 132

[20] Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy [J]. BLOOD ADVANCES, 2023, 7 (08) : 1606 - 1614

[11] Martínez-Laperche C, 2022, BMC CANCER, V22, DOI 10.1186/s12885-022-10070-z

[12] Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (30) : 3618 - +

[13] Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (12) : 1503 - 1510

[14] Lack of intrafollicular memory CD4+T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma [J]. BLOOD CANCER JOURNAL, 2021, 11 (07)

[15] Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial [J]. LANCET ONCOLOGY, 2020, 21 (11) : 1433 - 1442

[16] Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry [J]. LANCET ONCOLOGY, 2015, 16 (09) : 1111 - 1122

[17] Pettitt AR., 2019, HEMATOL ONCOL, V37, P67, DOI [DOI 10.1002/HON.35_2629, 10.1002/hon.35_2629]

[18] MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial [J]. LEUKEMIA, 2020, 34 (02) : 522 - 532

[19] Minimal Residual Disease Response at End of Induction and during Maintenance Correlates with Updated Outcome in the Phase III GALLIUM Study of Obinutuzumab- or Rituximab-Based Immunochemotherapy in Previously Untreated Follicular Lymphoma Patients [J]. BLOOD, 2018, 132

[20] Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy [J]. BLOOD ADVANCES, 2023, 7 (08) : 1606 - 1614